August 2013

Regorafenib is a recently approved oral, multikinase inhibitor for refractory colorectal cancer. Although structurally similar to sorafenib, it more potently inhibits a broader spectrum of critical growth receptor pathways, including those regulating angiogenesis and aberrant cellular proliferation.

Over the past two decades, there has been a shift away from indiscriminate cell-killing by anticancer agents toward the development of more specific drugs that target key aspects of cancer cell biology.

The use of tyrosine kinase inhibitors (TKIs) to inhibit BCR-ABL protein in chronic myeloid leukemia (CML) is one of the major milestones in modern oncology.

The efficacy of combining two immunotherapy agents will be assessed in a randomized, double-blind phase III study.

Clinical study results presented at the 2013 American Society of Clinical Oncology Annual Meeting may offer new hope for patients with chronic lymphocytic leukemia.

The dependence of cancer cells on the continued activity of specific oncogenes for proliferation and survival can be explored for drug development.

Long-term safety and efficacy results from COU-AA-302 in mCRPC, and efficacy and safety data for enzalutamide monotherapy were among the ASCO 2013 Annual Meeting presentations that extended clinically useful information for the care of patients with prostate cancer.

A dual-target PI3 kinase inhibitor demonstrated activity in several types of relapsed and refractory non-Hodgkin lymphoma.

The standard of care for metastatic renal-cell carcinoma (RCC) prevailed in a randomized comparison of everolimus and sunitinib as first-line therapy.

Dual HER2-targeted neoadjuvant therapy for early breast cancer did not significantly improve the pCR rate compared with a single anti-HER2 agent plus chemotherapy.

The presence or absence of RAS mutations should dictate use of panitumumab in combination with FOLFOX chemotherapy for patients with metastatic colorectal cancer.

Adding everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer and provided clues to the origin of trastuzumab resistance.